Experimental oncology最新文献

{"title":"VALIDATION OF A PANEL OF BIOMARKERS ASSOCIATED WITH AGGRESSIVE PHENOTYPE OF ENDOMETRIOID CARCINOMA OF ENDOMETRIUM.","authors":"L G Buchynska,&nbsp;N P Iurchenko,&nbsp;I P Nesina,&nbsp;N M Glushchenko","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-3.18513","DOIUrl":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-3.18513","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the prognostic significance of a panel of biomarkers for the identification of a highly malignant molecular subtype of endometrioid carcinoma of the endometrium (ECE).</p><p><strong>Materials and methods: </strong>The expression of a number of markers (CD24, CD44, E2F1, FOXP3, Her2/neu, p21WAF1/CIP1, p53, β-catenin, vimentin, Е-cadherin, с-Myc, cyclins D1 and Е1) was determined by the immunohistochemical method in the samples of resected tumors of 127 patients with ECE of I-II stage. The Kullback method and the PanelomiX web tool were used to assess the informativeness and identify the aggressive subtype of ECE. The associative relationships of the studied markers were determined using the STRING v11 database.</p><p><strong>Results: </strong>The study of the prognostic significance of a number of biomarkers in ECE has revealed the informativeness, high specificity and sensitivity (> 95%) of the р53+FOXP3-c-Myc+ phenotype, which is associated with a more aggressive tumor process. Bioinformatics analysis confirmed the correlative relationships between p53, FOXP3 and c-Myc, which are significant prognostic markers associated with cancer progression in ECE patients.</p><p><strong>Conclusions: </strong>The identified molecular phenotype of ECE (р53+FOXP3-c-Myc+) has differential and prognostic significance and objectively reflects a highly malignant subtype of this form of cancer.</p>","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 3","pages":"234-238"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40678318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EFFICACY OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ADULT BURKITT/BURKITT-LIKE LYMPHOMA: A SYSTEMATIC REVIEW.","authors":"U Joshi, R Subedi, G Nepal, S Gyawali, V Agrawal, B S Poudyal, V R Bhatt, Ch R D'Angelo","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-3.18599","DOIUrl":"10.32471/exp-oncology.2312-8852.vol-44-no-3.18599","url":null,"abstract":"<p><strong>Background: </strong>Burkitt and Burkitt like lymphoma (BL/BLL) are highly proliferative germinal or post-germinal B cell tumors. Few studies have evaluated the impact of autologous stem cell transplantation (ASCT) on disease outcomes.</p><p><strong>Aim: </strong>We performed a systematic review to analyze the efficacy of ASCT as frontline consolidation and for treatment of relapsed/refractory cases in adult BL/BLL.</p><p><strong>Materials and methods: </strong>Eligible studies with clear outcome measures on the efficacy of ASCT in adult patients with BL/BLL were identified through systematic search. The overall survival (OS), progression-free survival (PFS), complete response (CR), partial response (PR), and progression/relapse were used to assess the efficacy.</p><p><strong>Results: </strong>For patients who underwent ASCT in first CR, 5-year PFS and OS ranged between 70-78% and 70-83% respectively. For relapsed/refractory disease, 5-year PFS and OS were 27% and 31%, respectively. Patients undergoing ASCT for chemoresistant disease fared poorly with 3-year OS of 7% vs 37% for chemosensitive disease (p ≤ 0.00001). The overall response rate to ASCT for patients transplanted in first CR ranged between 71% and 93% and was 37% for patients who were transplanted in disease status other than first CR. Disease progression/relapse was observed in 16-29% of the patients transplanted in first CR, and 55% to 60% in relapsed disease.</p><p><strong>Conclusion: </strong>We found insufficient evidence to support ASCT over chemotherapy alone in the first remission for adult BL/BLL. Evidence supports guidelines recommending ASCT for chemosensitive disease but suggests there is no benefit to ASCT for chemoresistant disease.</p>","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 3","pages":"190-197"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40678314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MICRORNA-31 AS A POTENTIAL THERAPEUTIC BIOMARKER FOR ORAL SQUAMOUS CELL CARCINOMA: CURRENT EVIDENCE AND FUTURE PROSPECTS.","authors":"M Krishnan,&nbsp;S Babu,&nbsp;S Jayaraman,&nbsp;P Daniel,&nbsp;A Solomon,&nbsp;M Chinnaiyan","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-3.18569","DOIUrl":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-3.18569","url":null,"abstract":"","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 3","pages":"263-264"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40678316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PRIMARY CUTANEOUS ADENOID CYSTIC CARCINOMA IN THE TRUNK: CASE REPORT AND LITERATURE REVIEW.","authors":"M Moreno,&nbsp;Oliveira de,&nbsp;I Czarnobai,&nbsp;Boff Cássia","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-2.18006","DOIUrl":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.18006","url":null,"abstract":"<p><p>Primary cystic adenoid skin carcinoma is a rare and poorly documented neoplasm in literature worldwide, with just over 250 reports. This work describes a 52-year-old male patient, with no comorbidities, who presented this neoplasm in nodular format in the posterior thoracic region, associated with localized pain and erythema - symptoms that led him to seek medical help. The clinical findings, differential diagnosis and treatment particularities were reviewed and correlated with the clinical case. The choice of type of surgical treatment was done considering the characteristics of the primary lesion that are associated with a worse prognosis. Despite its rarity, this neoplasm is easily identified through histological examination, the correct choice of treatment and patient follow-up, essential to increase survival. Thus, this work contributes to diminish the scarcity of literature related to this topic, especially the form of treatment employed.</p>","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 2","pages":"174-176"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40707235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OECI 2022 ONCOLOGY DAYS AND GENERAL ASSEMBLY.","authors":"Ernestas Janulionis","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-2.17945","DOIUrl":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17945","url":null,"abstract":"<p><p>The OECI 2022 Oncology Days and the OECI General Assembly were held in Valencia (Spain) on June 15-17.</p>","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 2","pages":"93-94"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40707239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HUMAN MICROBIOTA AND BREAST CANCER.","authors":"Yu V Shvets,&nbsp;O O Lykhova,&nbsp;V F Chekhun","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-2.17855","DOIUrl":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17855","url":null,"abstract":"<p><p>Breast cancer is the leading malignancy in women worldwide. To date, much is known about the molecular subtypes of these malignant neoplasms and the mechanisms of drug resistance. Significant success has been achieved in approaches to early diagnosis, which allows identifying the tumor process in the early stages of development. Recently, the study of the influence of the human body microbiota on cancer development and the effectiveness of treatment has become an actively developing field of research. This review presents an analysis of the literature data on this issue.</p>","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 2","pages":"95-106"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40695912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"THE CHANGES OF NO LEVEL AND RNase ACTIVITY IN TUMOR TISSUE ACCOMPANYING THE PROGRESSION OF PROSTATE CANCER.","authors":"A P Burlaka,&nbsp;S V Virko,&nbsp;V M Grygorenko,&nbsp;O А Samoylenko,&nbsp;A V Verbinenko,&nbsp;V O Shlyakhovenko","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-2.17785","DOIUrl":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17785","url":null,"abstract":"<p><strong>Aim: </strong>To assess the inducible NO-synthase activity and the total RNase activity in tissue samples and blood neutrophils of the patients with prostate intraepithelial neoplasia (PIN) and prostate cancer (PCa) of different stages.</p><p><strong>Materials and methods: </strong>NO level was measured in tumor tissue and neutrophils of patients with PIN and PCa of different stages by electron paramagnetic resonance using the spin traps technology. RNase activity in tumor tissue of patients with PIN and PCa was measured by the method of zymography.</p><p><strong>Results: </strong>We have found that NO levels in prostate tumor tissue were significantly higher than in the PIN and increased along with the disease progression. Analysis of NO level in neutrophils of the PCa patients demonstrated that the values were not dispersed and did not depend on the stage of disease. NO level in neutrophils of the PCa patients increased manifold as compared with that in healthy donors. At the same time, the RNase activity in the prostate tumor tissue gradually decreased with PCa progression.</p><p><strong>Conclusion: </strong>Activities of inducible NO-synthase and RNases change significantly with progression of PCa.</p>","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 2","pages":"159-162"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40695915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"POLYAMINES AS NEW POTENTIAL BIOMARKERS FOR DIFFERENTIAL DIAGNOSIS OF PROSTATE CANCER AND ESTIMATION OF ITS AGGRESSIVENESS.","authors":"S P Zaletok,&nbsp;O O Klenov,&nbsp;V V Bentrad,&nbsp;M P Prylutskyi,&nbsp;Yu V Vitruk,&nbsp;E O Stakhovsky,&nbsp;A V Timoshenko","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-2.17758","DOIUrl":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17758","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) is one of the most common malignancies in older men. The study of tissue markers of PCa can provide information about the state of proliferation and apoptosis in tumors, the susceptibility of tumor cells to metastasis and the mechanisms of resistance to therapy, which, in turn, can help predict the course of the disease and develop personalized treatment. Polyamines (PAs) spermine, spermidine, putrescine are of particular interest in terms of PCa tissue markers.</p><p><strong>Aim: </strong>To investigate the levels of basic and acetylated forms of PAs in the postoperative samples of malignant and benign tumors of the human prostate and evaluate the possibility of their use for differential diagnosis and assessment of the PCa aggressiveness.</p><p><strong>Object and methods: </strong>57 postoperative tumor samples from patients with prostate adenocarcinoma of different Gleason score (GS) and clinical stage (T1-T4) and 20 samples of tumors from patients with benign prostate hyperplasia (BPH) were studied. The content of PAs was determined by high performance liquid chromatography.</p><p><strong>Results: </strong>Among the studied PAs, the most significant difference between PCa and BPH was observed for spermine (Spm). The level of Spm in PCa samples was 16 times lower than in BPH samples (p < 0.01). We did not find a significant dependence of PAs levels, including Spm, on the clinical stage. The association between the Spm level and the GS was established. The indolent (GS6) tumors were characterized by the highest Spm level while in the most aggressive (GS9 and GS10) tumors Spm content was the lowest.</p><p><strong>Conclusions: </strong>A sharp decrease in Spm levels is probably a characteristic feature of prostate malignant tumors. The obtained results indicate an association of Spm levels in tumors with the GS. This may indicate Spm involvement in the formation of the aggressiveness of PCa. The results of the study can be further used for differential diagnosis of prostate tumors and for assessing the aggressiveness of PCa.</p>","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 2","pages":"148-154"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40695916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"АNTIMETASTATIC EFFECT OF B. SUBTILIS IMV B-7724 LECTIN OBSERVED IN LEWIS LUNG CARCINOMA MODEL.","authors":"N I Fedosova,&nbsp;T V Symchych,&nbsp;N L Cheremshenko,&nbsp;A V Chumak,&nbsp;E V Koval,&nbsp;О М Karaman,&nbsp;I M Voyejkova","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-2.17914","DOIUrl":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17914","url":null,"abstract":"<p><strong>Aim: </strong>To study the antitumor and antimetastatic effects of B. subtilis IMV B-7724 lectin used in neoadjuvant and adjuvant settings in vivo.</p><p><strong>Materials and methods: </strong>Studies were performed on C57Bl/6J mice; Lewis lung carcinoma (LLC) was used as an experimental tumor. В. subtilis ІМV В-7724 lectin was administered to tumor-bearing mice or to mice which underwent surgical resection of the primary tumor. The lectin was injected subcutaneously, 10 times, at a single dose of 5 or 1 mg/kg of body weight. The standard indicators of tumor growth and metastasis were evaluated.</p><p><strong>Results: </strong>Independently of the application settings, the lectin at a dose of 1 mg/kg of b.w. caused more pronounced effect than at a dose of 5 mg/kg of b.w. The administration of B. subtilis IMV B-7724 lectin to the mice with LLC in neoadjuvant setting did not cause notable antitumor effect but led to a significant decrease in the number and volume of lung metastases. The lectin administration in adjuvant setting significantly inhibited metastasis: the metastasis inhibition index reached 63.0% and 100% in the mice treated with the lectin at a dose of 5 mg/kg and 1 mg/kg respectively. The mean survival time of the treated animals significantly increased.</p><p><strong>Conclusion: </strong>A pronounced antimetastatic effect of B. subtilis IMV B-7724 lectin administered in an adjuvant setting was demonstrated.</p>","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 2","pages":"155-158"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40695472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EXPRESSION OF miRNA AS PROGNOSTIC MARKERS OF RENAL CELL CARCINOMA COURSE.","authors":"Yu Vitruk,&nbsp;T Borikun,&nbsp;O Rossylna,&nbsp;T Zadvornyi,&nbsp;S Semko,&nbsp;O Voylenko,&nbsp;O Stakhovsky,&nbsp;A Shipko,&nbsp;E Stakhovsky","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-2.17883","DOIUrl":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17883","url":null,"abstract":"<p><p>Renal cell carcinoma (RCC) is one of the most common solid tumors in adults. There is a lack of reliable prognostic and predictive biomarkers for RCC course. Dysregulation of miRNAs expression has been reported to be involved in RCC progression. However, the data on miRNAs expression patterns in tumors are controversial.</p><p><strong>Aim: </strong>To investigate the expression and clinical significance of miR-99b, -144, -155, -210, -222, -302а, -377 in RCC ex vivo.</p><p><strong>Materials and methods: </strong>Retrospective analysis of the expression levels of miRNAs -99b, -144, -155, -210, -222, -302а, -377 in tumor tissue of 126 patients with clear cell RCC was performed using quantitative polymerase chain reaction.</p><p><strong>Results: </strong>Overexpression of miR-99b, -222, -302a and low levels of miR-155 in RCC tissues were significantly associated with advanced tumor stage (p < 0.05). In majority of patients with distant metastases (> 60%), high levels of miR-99b and 377 were detected (p < 0.05). High/low miR-99b, -144, -155, -210, -222, and -302a ratio was significantly associated with Fuhrman grade of tumors.</p><p><strong>Conclusion: </strong>Aberrant expression of miR-99b, -144, -155, -210, -222, -302а, -377 is strongly associated with advanced RCC, and panel of these miRNAs may be a useful prognostic marker for RCC course.</p>","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 2","pages":"132-136"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40695474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}